Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is the most common B-cell leukemia among older populations in Western countries. The clinical course of B-CLL is heterogeneous: in some patients the disease course is indolent, in others it is aggressive. The B-CLL subgroups with chromosome 11q23 deletion have been associated with aggressive disease course involving ATM deletion, extensive bulky lymphadenopathy (BLA), and inferior clinical outcome. Using real-time reverse transcriptase-polymerase chain reaction, we found that ATM was consistently underexpressed in B-CLL patients with BLA, irrespective of 11q23 deletion status. In addition, B-CLL patients who presented with BLA had a significantly shorter time to treatment (2 months) than did patients without BLA (74 months). Moreover, gene expression analysis in B-CLL patients with and without BLA revealed differences in expression for genes involved in apoptosis, cell cycle, and cell adhesion. These results indicate an association between BLA and reduced expression of ATM, suggesting a role for ATM in disease progression in B-CLL.

Original languageEnglish (US)
Pages (from-to)120-126
Number of pages7
JournalCancer genetics and cytogenetics
Volume172
Issue number2
DOIs
StatePublished - Jan 15 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Down-Regulation
B-Cell Leukemia
Gene Expression
Chromosome Deletion
Lymphadenopathy
Reverse Transcriptase Polymerase Chain Reaction
Cell Adhesion
Disease Progression
Real-Time Polymerase Chain Reaction
Cell Cycle
Apoptosis
Population

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

@article{27530ba10e5a43f895a3a244e22e4907,
title = "Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion",
abstract = "B-cell chronic lymphocytic leukemia (B-CLL) is the most common B-cell leukemia among older populations in Western countries. The clinical course of B-CLL is heterogeneous: in some patients the disease course is indolent, in others it is aggressive. The B-CLL subgroups with chromosome 11q23 deletion have been associated with aggressive disease course involving ATM deletion, extensive bulky lymphadenopathy (BLA), and inferior clinical outcome. Using real-time reverse transcriptase-polymerase chain reaction, we found that ATM was consistently underexpressed in B-CLL patients with BLA, irrespective of 11q23 deletion status. In addition, B-CLL patients who presented with BLA had a significantly shorter time to treatment (2 months) than did patients without BLA (74 months). Moreover, gene expression analysis in B-CLL patients with and without BLA revealed differences in expression for genes involved in apoptosis, cell cycle, and cell adhesion. These results indicate an association between BLA and reduced expression of ATM, suggesting a role for ATM in disease progression in B-CLL.",
author = "Joshi, {Avadhut D.} and Dickinson, {John D} and Hegde, {Ganapati V.} and Sanger, {Warren G.} and Armitage, {James Olen} and Bierman, {Philip Jay} and Bociek, {Robert G} and DeVetten, {Marcel P} and Vose, {Julie Marie} and Joshi, {Shantaram S}",
year = "2007",
month = "1",
day = "15",
doi = "10.1016/j.cancergencyto.2006.07.010",
language = "English (US)",
volume = "172",
pages = "120--126",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion

AU - Joshi, Avadhut D.

AU - Dickinson, John D

AU - Hegde, Ganapati V.

AU - Sanger, Warren G.

AU - Armitage, James Olen

AU - Bierman, Philip Jay

AU - Bociek, Robert G

AU - DeVetten, Marcel P

AU - Vose, Julie Marie

AU - Joshi, Shantaram S

PY - 2007/1/15

Y1 - 2007/1/15

N2 - B-cell chronic lymphocytic leukemia (B-CLL) is the most common B-cell leukemia among older populations in Western countries. The clinical course of B-CLL is heterogeneous: in some patients the disease course is indolent, in others it is aggressive. The B-CLL subgroups with chromosome 11q23 deletion have been associated with aggressive disease course involving ATM deletion, extensive bulky lymphadenopathy (BLA), and inferior clinical outcome. Using real-time reverse transcriptase-polymerase chain reaction, we found that ATM was consistently underexpressed in B-CLL patients with BLA, irrespective of 11q23 deletion status. In addition, B-CLL patients who presented with BLA had a significantly shorter time to treatment (2 months) than did patients without BLA (74 months). Moreover, gene expression analysis in B-CLL patients with and without BLA revealed differences in expression for genes involved in apoptosis, cell cycle, and cell adhesion. These results indicate an association between BLA and reduced expression of ATM, suggesting a role for ATM in disease progression in B-CLL.

AB - B-cell chronic lymphocytic leukemia (B-CLL) is the most common B-cell leukemia among older populations in Western countries. The clinical course of B-CLL is heterogeneous: in some patients the disease course is indolent, in others it is aggressive. The B-CLL subgroups with chromosome 11q23 deletion have been associated with aggressive disease course involving ATM deletion, extensive bulky lymphadenopathy (BLA), and inferior clinical outcome. Using real-time reverse transcriptase-polymerase chain reaction, we found that ATM was consistently underexpressed in B-CLL patients with BLA, irrespective of 11q23 deletion status. In addition, B-CLL patients who presented with BLA had a significantly shorter time to treatment (2 months) than did patients without BLA (74 months). Moreover, gene expression analysis in B-CLL patients with and without BLA revealed differences in expression for genes involved in apoptosis, cell cycle, and cell adhesion. These results indicate an association between BLA and reduced expression of ATM, suggesting a role for ATM in disease progression in B-CLL.

UR - http://www.scopus.com/inward/record.url?scp=33845929201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845929201&partnerID=8YFLogxK

U2 - 10.1016/j.cancergencyto.2006.07.010

DO - 10.1016/j.cancergencyto.2006.07.010

M3 - Article

C2 - 17213020

AN - SCOPUS:33845929201

VL - 172

SP - 120

EP - 126

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -